- Home
- AGIO vs BDJ Comparison
AGIO vs BDJ Comparison
Compare AGIO & BDJ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGIO
- BDJ
- Stock Information
- Founded
- AGIO 2007
- BDJ 2005
- Country
- AGIO United States
- BDJ United States
- Employees
- AGIO N/A
- BDJ N/A
- Industry
- AGIO Biotechnology: Pharmaceutical Preparations
- BDJ Finance Companies
- Sector
- AGIO Health Care
- BDJ Finance
- Exchange
- AGIO Nasdaq
- BDJ Nasdaq
- Market Cap
- AGIO 1.4B
- BDJ 1.6B
- IPO Year
- AGIO 2013
- BDJ N/A
- Fundamental
- Price
- AGIO $35.00
- BDJ $8.69
- Analyst Decision
- AGIO Buy
- BDJ
- Analyst Count
- AGIO 6
- BDJ 0
- Target Price
- AGIO $57.40
- BDJ N/A
- AVG Volume (30 Days)
- AGIO 840.6K
- BDJ 561.6K
- Earning Date
- AGIO 07-31-2025
- BDJ 01-01-0001
- Dividend Yield
- AGIO N/A
- BDJ 8.85%
- EPS Growth
- AGIO N/A
- BDJ N/A
- EPS
- AGIO 11.13
- BDJ N/A
- Revenue
- AGIO $40,875,000.00
- BDJ N/A
- Revenue This Year
- AGIO $18.94
- BDJ N/A
- Revenue Next Year
- AGIO $201.70
- BDJ N/A
- P/E Ratio
- AGIO $3.15
- BDJ N/A
- Revenue Growth
- AGIO 30.57
- BDJ N/A
- 52 Week Low
- AGIO $23.42
- BDJ $6.91
- 52 Week High
- AGIO $62.58
- BDJ $8.66
- Technical
- Relative Strength Index (RSI)
- AGIO 38.99
- BDJ 42.08
- Support Level
- AGIO $37.09
- BDJ $8.71
- Resistance Level
- AGIO $39.12
- BDJ $8.89
- Average True Range (ATR)
- AGIO 1.78
- BDJ 0.09
- MACD
- AGIO -0.67
- BDJ -0.02
- Stochastic Oscillator
- AGIO 9.16
- BDJ 18.52
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
About BDJ Blackrock Enhanced Equity Dividend Trust
BlackRock Enhanced Equity Dividend Trust is a United States closed-end management investment company. Its investment objective is to seek current income and current gains, with a secondary objective of long-term capital appreciation.